
Intellia Therapeutics Inc
NASDAQ:NTLA

Intrinsic Value
The intrinsic value of one
NTLA
stock under the Base Case scenario is
22.17
USD.
Compared to the current market price of 9.16 USD,
Intellia Therapeutics Inc
is
Undervalued by 59%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Intellia Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Intellia Therapeutics Inc
Balance Sheet Decomposition
Intellia Therapeutics Inc
Current Assets | 551.4m |
Cash & Short-Term Investments | 503.7m |
Receivables | 10.5m |
Other Current Assets | 37.1m |
Non-Current Assets | 434.8m |
Long-Term Investments | 228.1m |
PP&E | 163.1m |
Other Non-Current Assets | 43.6m |
Free Cash Flow Analysis
Intellia Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Intellia Therapeutics Inc
Revenue
|
45.6m
USD
|
Operating Expenses
|
-586.6m
USD
|
Operating Income
|
-541.1m
USD
|
Other Expenses
|
15.2m
USD
|
Net Income
|
-525.9m
USD
|
NTLA Profitability Score
Profitability Due Diligence
Intellia Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Score
Intellia Therapeutics Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
NTLA Solvency Score
Solvency Due Diligence
Intellia Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Score
Intellia Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NTLA Price Targets Summary
Intellia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
NTLA
is 42.5 USD
with a low forecast of 8.08 USD and a high forecast of 111.3 USD.
Dividends
Current shareholder yield for NTLA is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
NTLA
stock under the Base Case scenario is
22.17
USD.
Compared to the current market price of 9.16 USD,
Intellia Therapeutics Inc
is
Undervalued by 59%.